Cloud SaaS Solutions Will Drive Digital Forensics Adoption

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

26 Apr 25

Updated

10 Dec 25

Views

156

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-11.8%

7D

-2.9%

Loading

1Y

-11.8%

7D

-2.9%

You can edit this narrative until Dec 11 7:05 AM. Then, changes will post as Updates.

Author's Valuation

US$24.7127.8% undervalued

AnalystConsensusTarget Fair Value

Shared on 10 Dec 25

CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead

Narrative Update on Cellebrite DI Analysts have modestly raised their price target on Cellebrite DI to approximately $24.71 per share, reflecting slightly higher long term revenue growth and profit margin expectations that more than offset a marginally higher assumed discount rate and a modestly lower future P/E multiple. What's in the News Cellebrite DI issued revenue guidance for the fourth quarter of 2025, projecting between $123 million and $128 million, representing annual growth of 13% to 17% (company guidance).

Shared on 26 Nov 25

Fair value Increased 6.79%

CLBT: Profit Margins Will Drive Improved Earnings Outlook Into Next Year

Analysts have raised their price target for Cellebrite DI from $23.14 to $24.71. This change reflects increased confidence in the company’s stronger profit margins and revenue growth outlook.

Shared on 23 Sep 25

Fair value Increased 2.53%

Cellebrite DI’s consensus price target was modestly raised to $23.14 as analysts anticipate near-term revenue softness due to U.S. federal budget constraints and delayed deal timing, while seeing future upside from eventual deal catch-up and FedRAMP progress. Analyst Commentary Slower-moving Q1 deals in Europe were completed in Q2, but persistent softness in U.S. federal deals is expected to continue until at least October, impacting near-term revenue.

Shared on 15 Aug 25

Fair value Decreased 1.86%

Cellebrite DI’s consensus price target held steady at $23.00 as analysts factor in near-term headwinds from delayed federal spending and efficiency impacts, yet remain positive about long-term growth driven by healthy demand and anticipated federal certifications. Analyst Commentary Lowered Q2 results and second half guidance due to ongoing efficiency impacts and customer budget pauses.

Shared on 01 May 25

Fair value Decreased 5.29%

AnalystConsensusTarget Fair Value

US$24.71

27.8% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

15.29%

Software revenue growth rate

1.22%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

10.63%

Calculation

US$169.20m

Earnings '28

x

50.71x

PE Ratio '28

=

US$8.58b

Market Cap '28

US$8.58b

Market Cap '28

/

256.04m

No. shares '28

=

US$33.51

Share Price '28

US$33.51 Share Price '28

Discounted to 2025 @ 10.69% p.a.

=

US$24.71

Fair Value '25